Delta 9-tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rat: blockade of dopaminergic effects with HA966

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
J D JentschR H Roth

Abstract

The present study examined delta 9-tetrahydrocannabinol (THC)-induced alterations in monoamine transmission in the rat forebrain as well as the effects of the enantiomers of 3-amino-1-hydroxypyrrolid-2-one (HA966) on the monoamine response to THC. Activation of dopamine (DA) and norepinephrine (NE) but not serotonin (5-HT) turnover in the prefrontal cortex (PFC) was observed after THC (5 mg/kg i.p.) administration. Both enantiomers of HA966 completely prevented the effects of THC on PFC DA turnover and partially blocked the THC-induced rise in NE metabolism. The cognitive consequences of THC exposure were also examined. THC significantly impaired spatial working, but not reference, memory in rats, and this effect was ameliorated by HA966. Thus, HA966 prevents the THC-induced increases in PFC DA turnover and impairments of prefrontal cortical working memory function. Furthermore, these data suggest that cognitive impairments displayed by marijuana self-administering humans may be related to PFC DA hyperactivity and that HA966 may prevent this effect.

Citations

Aug 4, 2004·Psychopharmacology·P Alexander Arguello, J David Jentsch
Jul 18, 2009·European Archives of Psychiatry and Clinical Neuroscience·Deepak Cyril D'SouzaMohini Ranganathan
Oct 3, 2003·European Journal of Pharmacology·Carmen MazzolaFilippo Drago
Aug 9, 2002·European Journal of Pharmacology·Roberto CiccocioppoMaurizio Massi
Jul 20, 2002·Neuropharmacology·S N DaviesG Riedel
Mar 13, 2002·Pharmacology, Biochemistry, and Behavior·Peter OlaussonBo Söderpalm
Mar 20, 2002·Pharmacology, Biochemistry, and Behavior·Robert I BlockNancy C Andreasen
Jan 31, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·SilvaGeorgeE Da, Reinaldo N Takahashi
Jan 13, 2000·Progress in Neuro-psychopharmacology & Biological Psychiatry·E M Nakamura-PalaciosC F Gomes
Aug 26, 1998·Drug and Alcohol Dependence·S R Childers, C S Breivogel
Jul 16, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Colm M P O'TuathaighJohn L Waddington
Jan 6, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Christopher D VerricoDavid A Lewis
Sep 24, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·June M YoungPaul E Mallet
Sep 24, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Petra MakelaRobert D Rogers
May 14, 2008·The Australian and New Zealand Journal of Psychiatry·Martin CohenVaughan Carr
Apr 7, 2007·Schizophrenia Bulletin·Hywel J WilliamsMichael C O'Donovan
Aug 5, 2009·Addiction Biology·Krista Lisdahl MedinaSusan F Tapert
Sep 16, 2005·Psychopharmacology·Lívia Carla Silva de MeloEster Miyuki Nakamura-Palacios
Dec 31, 2005·Naunyn-Schmiedeberg's Archives of Pharmacology·Onintza SagredoRosario de Miguel
Mar 19, 2014·Psychopharmacology·Tim RuhlGerhard von der Emde
Dec 10, 2014·Expert Opinion on Drug Discovery·Ryan WyrofskyElisabeth J Van Bockstaele
Dec 29, 2015·Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association·Kavelin RumallaManoj K Mittal
Mar 6, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·Francis Rodriguez BambicoGabriella Gobbi
Feb 3, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·Ana Franky Carvalho, Elisabeth J Van Bockstaele
Sep 10, 2010·Schizophrenia Research·José Manuel Rodríguez-SánchezBenedicto Crespo-Facorro
Nov 14, 2008·Journal of Substance Abuse Treatment·Scott M Hyman, Rajita Sinha
Jul 21, 2015·Gene·Randall G Krug, Karl J Clark
Sep 6, 2015·The International Journal of Neuropsychopharmacology·Marie FitzgibbonMichelle Roche
Apr 8, 2016·Nature Reviews. Neuroscience·H Valerie CurranLoren H Parsons
May 19, 2006·The European Journal of Neuroscience·Anna Lisa MuntoniMarco Pistis
Oct 15, 2008·Expert Opinion on Therapeutic Targets·Francis Rodriguez Bambico, Gabriella Gobbi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.